Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10709995 | 0.76 | SMN1; SMN2 (0.44) | SMN1; SMN2 | |
| SCHEMBL20486787 | 0.75 | KDM4E (0.41) | SLC6A4SMN1; SMN2HTR2AHTR2CERN1 | |
| SCHEMBL3417280 | 0.75 | ERN1 (0.40) | SMN1; SMN2HTR2AHTR2CERN1 | |
| SCHEMBL20298587 | 0.74 | MDM2 (0.39) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16973507 | 0.74 | ALDH1A1 (0.43) | — | |
| SCHEMBL8008022 | 0.71 | RXRA (0.39) | — | |
| SCHEMBL895659 | 0.71 | CYP2D6 (0.49) | SLC6A4HTR2AHTR2C | |
| SCHEMBL669891 | 0.71 | CYP2D6 (0.49) | SLC6A4HTR2AHTR2C | |
| SCHEMBL29429683 | 0.71 | CYP2D6 (0.49) | SLC6A4HTR2AHTR2C | |
| SCHEMBL896090 | 0.71 | CYP2D6 (0.49) | SLC6A4HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190169207-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169207-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, DAPK2 | SLC6A2 4872/4885SLC6A4 4844/4885SLC6A3 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.